Brief: Hansa Biopharma Provides Business Update Including Certain Key Financials

Hansa Biopharma AB

09/01/2022 07:04

Jan 9 (Reuters) - Hansa Biopharma AB  HNSA.ST :
    * HANSA BIOPHARMA PROVIDES BUSINESS UPDATE INCLUDING CERTAIN
KEY
FINANCIALS
    * YEAR-END CASH POSITION OF SEK 889 MILLION; HANSA FINANCED
INTO
2023, AS PREVIOUSLY GUIDED
    * HANSA TO EXPLORE DESENSITIZATION TREATMENT IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
    * FIRST PATIENTS ENROLLED INTO PIVOTAL U.S. CONFIDES STUDY
    * AGREEMENT ESTABLISHED WITH ASKBIO TO EVALUATE FEASIBILITY
OF
IMLIFIDASE AS PRE-TREATMENT AHEAD OF GENE THERAPY IN POMPE
DISEASE
    * HANSA EXPECTS TO COMMENCE PAS DURING 2022 IN EUROPE, IN
WHICH
APPROX 50 HIGHLY SENSITIZED PATIENTS WILL BE TREATED WITH
IMLIFIDASE
    * FOR FINANCIAL YEAR 2021, TOTAL REVENUE AMOUNTS TO
APPROXIMATELY
SEK 34 MILLION AND TOTAL OPERATING LOSS APPROXIMATELY SEK 547
MILLION

Source text for Eikon:  ID:nWkr61jpbm 
Further company coverage:  HNSA.ST 

 ((reuters.briefs@thomsonreuters.com;))